296 related articles for article (PubMed ID: 7890531)
21. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer.
Pinson P; Joos G; Watripont P; Brusselle G; Pauwels R
Respiration; 1997; 64(1):102-7. PubMed ID: 9044484
[TBL] [Abstract][Full Text] [Related]
22. The value of tumour markers in lung cancer.
Gomm SA; Keevil BG; Thatcher N; Hasleton PS; Swindell RS
Br J Cancer; 1988 Dec; 58(6):797-804. PubMed ID: 2906254
[TBL] [Abstract][Full Text] [Related]
23. [Clinical value of measurement of serum creatine kinase BB and neuron specific enolase for small cell lung cancer].
Zhou J; Xiong Q
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Mar; 26(1):90-3. PubMed ID: 7657349
[TBL] [Abstract][Full Text] [Related]
24. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
25. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal immunoradiometric assay and polyclonal radioimmunoassay compared for measuring neuron-specific enolase in patients with lung cancer.
Body JJ; Paesmans M; Sculier JP; Dabouis G; Bureau G; Libert P; Berchier MC; Raymakers N; Klastersky J
Clin Chem; 1992 May; 38(5):748-51. PubMed ID: 1316245
[TBL] [Abstract][Full Text] [Related]
27. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
28. Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer.
Nutini S; Cappelli G; Benucci A; Catalani C; Nozzoli F
Int J Biol Markers; 1990; 5(4):198-202. PubMed ID: 1965544
[TBL] [Abstract][Full Text] [Related]
29. [Role of the cut-off value of serum neuron-specific enolase in differentiating small cell lung cancer from non-small cell lung cancer].
Wei T; Luo RC; Zuo Q; Zhang JY; Miao JX; Lu HF
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):858-9. PubMed ID: 16793621
[TBL] [Abstract][Full Text] [Related]
30. Fucosyl-GM1 in small-cell lung cancer. A comparison with the tumour marker neuron-specific enolase.
Drivsholm L; Vangsted A; Pallesen T; Hansen M; Dombernowsky P; Hirsch F; Hansen HH
Ann Oncol; 1994 Sep; 5(7):623-6. PubMed ID: 7993838
[TBL] [Abstract][Full Text] [Related]
31. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis.
Giovanella L; Piantanida R; Ceriani L; Bandera M; Novario R; Bianchi L; Roncari G
Int J Biol Markers; 1997; 12(1):22-6. PubMed ID: 9176714
[TBL] [Abstract][Full Text] [Related]
32. Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma.
van de Pol M; Twijnstra A; ten Velde GP; Menheere PP
J Neurooncol; 1994; 19(2):149-54. PubMed ID: 7964990
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer.
Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G
Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058
[TBL] [Abstract][Full Text] [Related]
34. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
35. Serum levels of neuron-specific enolase, carbohydrate antigen 19-9 and carbohydrate antigen 125 in carcinoma of the lung.
Oktay G; Güner G; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1995 May; 23(2):211S. PubMed ID: 7672232
[No Abstract] [Full Text] [Related]
36. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
[TBL] [Abstract][Full Text] [Related]
37. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
[TBL] [Abstract][Full Text] [Related]
39. Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer.
Scagliotti GV; Piani M; Gatti E; Gozzelino F; Albera C; Pozzi E
Eur Respir J; 1989 Sep; 2(8):746-50. PubMed ID: 2553476
[TBL] [Abstract][Full Text] [Related]
40. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).
Jørgensen LG; Osterlind K; Hansen HH; Cooper EH
Br J Cancer; 1994 Oct; 70(4):759-61. PubMed ID: 7917935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]